Sonoma Pharmaceuticals (SNOA)
(Delayed Data from NSDQ)
$0.24 USD
+0.01 (5.08%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.24 0.00 (-0.83%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.24 USD
+0.01 (5.08%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.24 0.00 (-0.83%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
Zacks News
Beat the Market Like Zacks: Starbucks, Shopify, 3M in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Sonoma Pharmaceuticals (SNOA) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Sonoma Pharmaceuticals (SNOA) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Sonoma Up on FDA Approval of Antimicrobial Post-Therapy Gel
by Zacks Equity Research
Sonoma's (SNOA) shares gain after the FDA approves its antimicrobial post-therapy gel for the management of post-non-ablative laser therapy procedures.